Showing results (1-10 of 96) with videos related to
Sort By:
Pageof 10
Current Treatment Options in Oncology|October 27, 2025
Immunotherapy-associated Cardiotoxicity: a Comprehensive Review of Checkpoint inhibitors, monoclonal, cellular, and cytokine-based TreatmentsKalliopi Keramida, Theodora-Christina Kyriakou, Athos Antoniades, et al.Biochimica Et Biophysica Acta. Molecular Cell Research|June 25, 2019
Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunitiesMingchuan Li, Michele Russo, Flora Pirozzi, et al.Current Treatment Options in Oncology|February 6, 2021
Metabolic Aspects of Anthracycline CardiotoxicityMichele Russo, Angela Della Sala, Carlo Gabriele Tocchetti, et al.British Journal of Clinical Pharmacology|February 23, 2021
Cardiovascular safety of the tyrosine kinase inhibitor nintedanibPietro Ameri, Giacomo Tini, Paolo Spallarossa, et al.Heart Failure Reviews|November 23, 2021
Prognostic impact of diabetes in chronic and acute heart failureStefano Ghio, Valentina Mercurio, Andrea Attanasio, et al.Current Drug Targets|March 10, 2015
Endogenous Cardioprotective Agents: Role in Pre and PostconditioningClaudia Penna, Riccarda Granata, Carlo Gabriele Tocchetti, et al.Antioxidants & Redox Signaling|April 12, 2022
Janus, or the Inevitable Battle Between Too Much and Too Little OxygenDaniele Mancardi, Sara Ottolenghi, Umberto Attanasio, et al.Frontiers in Immunology|April 18, 2022
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse EventsRemo Poto, Teresa Troiani, Gjada Criscuolo, et al.Cardiovascular Research|May 13, 2020
Stimulating pro-reparative immune responses to prevent adverse cardiac remodelling: consensus document from the joint 2019 meeting of the ESC Working Groups of cellular biology of the heart and myocardial functionSabine Steffens, Sophie Van Linthout, Joost P G Sluijter, et al.ESMO Open|November 7, 2017
Cardiotoxicity of immune checkpoint inhibitorsGilda Varricchi, Maria Rosaria Galdiero, Giancarlo Marone, et al.Pageof 10